Honest Company Inc vs Relay Therapeutics Inc. Common Stock — how do they compare? Honest Company Inc trades at $5.05 (market cap $533.20M), while Relay Therapeutics Inc. Common Stock trades at $17.89 (market cap $3.82B). The key difference: Relay Therapeutics Inc. Common Stock is far larger — about 7.2× Honest Company Inc's market cap, and Relay Therapeutics Inc. Common Stock is more actively traded (4,332,079 versus 1,990,155). Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| HNST | RLAY | |
|---|---|---|
Market Cap | $533.20M | $3.82B |
Volume | 1,990,155 | 4,332,079 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $20.75 |
52-Week Low | $2.10 | $6.03 |
Typical Hold Time | 39 Days | 0 Days |
Enterprise Value | $436.81M | $2.93B |
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.07, up 2.84% today, but remains in a bearish technical trend. The company shows mixed fundamentals with declining revenue to $371.32M in 2025 and a net loss of -$15.69M, though Q2 2026 earnings beat expectations. Analyst sentiment is cautious with a $5.30 consensus target, while institutional buying from BlackRock and Deutsche Bank provides some support.
The outlook remains challenging with persistent profitability issues and competitive pressures. While strategic exits show early promise and cash flow improved to $14.15M in 2025, investors face risks from margin compression and uncertain growth trajectory. The stock trades at premium valuations despite negative returns, requiring careful risk assessment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →